

## SWOG Cancer Research Network-led oral and poster presentations at ASCO 2023

All times are Central Time

Information on publication-only abstracts and presentations led by other NCTN groups with contributions from SWOG investigators is available [on the SWOG website](#).

Study # & Disease Site	Saturday, June 3, 2023	What, Where, & When
S0931 Genitourinary Cancer	Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931) First Author: <b>Shuchi Gulati</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Kidney and Bladder Abstract #: 4546 Poster Bd #: 38 June 3, 8 – 11 am, Hall A & On Demand
S1216 Genitourinary Cancer	Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide First Author: <b>Amir Goldkorn</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract #: 5080 Poster Bd #: 174 June 3, 8 – 11 am, Hall A & On Demand
S1216 Genitourinary Cancer	Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel First Author: <b>Primo N. Lara</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract #: 5048 Poster Bd #: 142 June 3, 8 – 11 am, Hall A & On Demand
S1216 Genitourinary Cancer	Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216) First Author: <b>Mamta Parikh</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract #: 5074 Poster Bd #: 168 June 3, 8 – 11 am, Hall A & On Demand
S1500 Genitourinary Cancer	Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial First Author: <b>Abhishek Tripathi</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Kidney and Bladder Abstract #: 4562 Poster Bd #: 54 June 3, 8 – 11 am, Hall A & On Demand
S1802 Genitourinary Cancer	HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) First Author: <b>Daniel Bsteh</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract #: 5036 Poster Bd #: 130 June 3, 8 – 11 am, Hall A & On Demand

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2023

S1937 Genitourinary Cancer	A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 First Author: <b>Sarmad Sadeghi</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Kidney and Bladder Abstract #: TPS4608 Poster Bd #: 96b June 3, 8 – 11 am, Hall A & On Demand
Multiple Trials	SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities First Author: <b>Antoine Morin Coulombe</b>	<b>Poster Session</b> Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract #: TPS5103 Poster Bd #: 194b June 3, 8 – 11 am, Hall A & On Demand
S1216 Genitourinary Cancer	Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial First Author: <b>Nicolas Sayegh</b>	<b>Poster Session</b> Session: Health Services Research and Quality Improvement Abstract #: 6532 Poster Bd #: 24 June 3, 1:15 – 4:15 pm, Hall A & On Demand
S2000 Melanoma	A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 First Author: <b>Zeynep Eroglu</b>	<b>Poster Session</b> Session: Melanoma/Skin Cancers Abstract #: TPS9603 Poster Bd #: 360b June 3, 1:15 – 4:15 pm, Hall A & On Demand
Multiple Trials	Association of measures of socioeconomic deprivation with healthcare utilization in elderly patients enrolled in SWOG cancer clinical trials First Author: <b>Dawn L. Hershman</b>	<b>Poster Session</b> Session: Health Services Research and Quality Improvement Abstract #: 6527 Poster Bd #: 19 June 3, 1:15 – 4:15 pm, Hall A & On Demand
S1609 DART Early Therapeutics & Rare Cancers (Sarcoma)	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27) First Author: <b>Young Kwang Chae</b>	<b>Poster Discussion Session</b> Session: Sarcoma Abstract #: 11516 Poster Bd #: 450 June 3, 1:15 – 4: 15 pm & 4:30 pm, S404 & On Demand
S1929 Lung Cancer	SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC) First Author: <b>Nagla Fawzy Abdel Karim</b>	<b>Oral Abstract Session</b> Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Abstract #: 8504 June 3, 4:12 pm, Hall B1 & Live Stream

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2023

Study # & Disease Site	Sunday, June 4, 2023	What, Where, & When
S0226 Breast Cancer	Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226 First Author: <b>Erin Frances Cobain</b>	<b>Poster Session</b> Session: Breast Cancer—Metastatic Abstract #: 1076 Poster Bd #: 297 June 4, 8 – 11 am, Hall A & On Demand
S1900E Lung-MAP Lung Cancer	ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC) First Author: <b>Sukhmani Kaur Padda</b>	<b>Poster Session</b> Session: Lung Cancer—Non-Small Cell Metastatic Abstract #: TPS9143 Poster Bd #: 129a June 4, 8 – 11 am, Hall A & On Demand
Lung-MAP Lung Cancer	The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP First Author: <b>Philip C. Mack</b>	<b>Poster Session</b> Session: Lung Cancer—Non-Small Cell Metastatic Abstract #: 9035 Poster Bd #: 23 June 4, 8 – 11 am, Hall A & On Demand
S1609 DART Early Therapeutics & Rare Cancers	Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609) First Author: <b>Megan Othus</b>	<b>Oral Abstract Session</b> Session: Developmental Therapeutics—Immunotherapy Abstract #: 2504 June 4, 10:49 am, Arie Crown Theater & Live Stream
S1826 Lymphoma	SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL) First Author: <b>Alex Francisco Herrera</b>	<b>Plenary Session</b> Session: Plenary Session Abstract #: LBA4 June 4, 2:53 pm, Hall B1 & Live Stream

SWOG Cancer Research Network-led oral and poster presentations at ASCO 2023

Study # & Disease Site	Monday, June 5, 2023	What, Where, & When
S0777 Multiple Myeloma	Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data First Author: <b>Brian G. Durie</b>	<b>Poster Session</b> Session: Hematologic Malignancies—Plasma Cell Dyscrasia Abstract #: 8037 Poster Bd #: 29 June 5, 8 – 11 am, Hall A & On Demand
S1505 Gastrointestinal Cancer	Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505 First Author: <b>Sameer H. Patel</b>	<b>Poster Session</b> Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Disease Abstract #: 4158 Poster Bd #: 479 June 5, 8 – 11 am, Hall A & On Demand
S2001 Gastrointestinal Cancer	Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001 First Author: <b>Vincent Chung</b>	<b>Poster Session</b> Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Abstract #: TPS4198 Poster Bd #: 505b June 5, 8 – 11 am, Hall A & On Demand
S1714 Symptom Control & Quality of Life	Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714 First Author: <b>Meghna S. Trivedi</b>	<b>Oral Abstract Session</b> Session: Symptoms and Survivorship Abstract #: 12003 June 5, 9:00 am, S100a & Live Stream
Multiple Trials	Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials First Author: <b>Joseph M. Unger</b>	<b>Poster Session</b> Session: Care Delivery and Regulatory Policy Abstract #: 1565 Poster Bd #: 159 June 5, 1:15 – 4:15 pm, Hall A & On Demand
S1609 DART Early Therapeutics & Rare Cancers (Gynecologic Cancer)	A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers First Author: <b>Young Kwang Chae</b>	<b>Poster Discussion Session</b> Session: Gynecologic Cancer Abstract #: 5517 Poster Bd #: 211 June 5, 1:15 – 4:15 & 4:54 pm, S100bc & On Demand
S1011 Genitourinary Cancer	SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer First Author: <b>Seth P. Lerner</b>	<b>Oral Abstract Session</b> Session: Genitourinary Cancer—Kidney and Bladder Disease Abstract #: 4508 June 5, 1:54 pm, Hall D1 & Live Stream